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data from the United States. METHODS: We obtained data on jury awards for injuries
that caused functional disabilities similar to RA. We identiﬁ ed a sample of jury awards 
involving limb disabilities and/or losses. With these award amounts, we computed the
average jury award and calculated its annuity equivalence, assuming an average US
life expectancy. For RA-associated early mortality, we employed data from the medical 
literature to compute the difference between the present value of sex-speciﬁ c lifetime
earnings of RA patients, with adjustments to reﬂ ect reduced life expectancy and 
average lifetime earnings in the United States. Tangible costs associated with RA 
(e.g., health care, workplace, paid/unpaid help, government disability) were derived 
from private insurance, Medicare, and Medicaid claims databases; disability and
medical absence data; and the literature. Patient-level cost estimates were weighted by 
the prevalence of relevant populations to compute societal costs (2005 US dollars).
RESULTS: The average annuity per jury award for injuries similar to RA disabilities 
was $55,700. This corresponds to an annual societal value of disability/QOL deterio-
ration of $10.8 billion. The annualized reduction in lifetime earnings per RA patient
(vs. those without RA) was $7,420, or $9.6 billion in total. Thus, the annual intangible 
costs of functional disability/QOL and mortality totaled $20.4 billion. Total tangible
societal costs were $19.3 billion ($8.4 billion for direct costs [patient health care]; and 
$10.9 billion for indirect costs [other RA consequences]). CONCLUSIONS: Including 
intangible costs increased the annual societal costs of RA by $20.4 billion in the United
States, for a total of $39.7 billion.
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OBJECTIVES: 1) To assess the associations of EQ-5D index score, EQ-VAS, and seven
estimated utilities with self-reported stroke in a U.S. national representative sample, 
and 2) To compare estimated utilities with EQ-5D and EQ-VAS in both stroke and 
non-stroke samples. METHODS: Data were extracted from the 2001 Household
Component of the Medical Expenditure Panel Survey(MEPS). Seven estimated utilities 
were derived from the SF-12v1, including HUI3/VAS item models(IM) and categori-
cal models(CM) from the Sengupta-Nichol, Brazier SF-6D, Lundberg VAS, and Sullivan 
EQ-5D algorithms. An analysis of covariance was used to determine differences in 
mean utility scores between individuals with and without stroke. Covariate(social-
demographic and comorbidity) adjusted effect sizes(ES) were calculated for utilities
between individuals with and without stroke, as well as between estimated utilities and
EQ-5D/EQ-VAS. RESULTS: A total of 19,475 individuals completed SF-12v1, EQ-
5D, and EQ-VAS. Mean age was 42.2 years, 40% were female, 14% had self-reported 
stroke. Individuals with stroke had signiﬁ cantly lower covariate adjusted mean EQ-5D
(0.16 points difference), EQ-VAS (0.14 points difference), and estimated utilities (0.11
or 0.12 points differences) when compared to those without stroke(all p  0.0001). 
Stroke individuals showed large effect in utility scores when compared to non-stroke
individuals. HUI3-IM (ES  1.20) and HUI3-CM (ES  1.22) showed ES similar to 
EQ-5D (ES  1.23), and both VAS-IM and VAS-CM (ES  1.09) had ES similar to 
EQ-VAS (ES  1.08). When comparing estimated utilities with EQ-5D, Sullivan EQ-5D 
(ES  0.26) and SF-6D(ES  0.29) showed small effect, while other estimated utilities
showed no effect in stroke individuals; all estimated utilities showed small (ES  0.23
for Sullivan EQ-5D) to large effect (ES  1.00 for SF-6D) in non-stroke individuals.
CONCLUSIONS: EQ-5D, EQ-VAS and estimated utilities in stroke individuals dis-
played clinical meaningful differences from those without stroke. Derived HUI3/VAS
showed the similarity with the EQ-5D/EQ-VAS in stroke individuals. Our ﬁ ndings
indicated that EQ-5D, EQ-VAS, and estimated HUI3 and VAS were sensitive to health
state and could be used for cost-effectiveness analysis in stroke individuals.
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OBJECTIVES: To establish an item bank for Computer Adaptive Measure of Func-
tional Cognition for Stroke (CAMFC-S). The prerequisite for monitoring the effective-
ness of pharmaceutical interventions for stroke-related cognitive deﬁ cits is the
development of reliable and valid cognitive measures. Existing measures of post-stroke 
cognition: 1) are few in number; 2) lack precision and efﬁ ciency for stroke; and 3) fail 
to reﬂ ect cognitive functioning that is related to everyday activities (i.e., “functional 
cognition”). METHODS: A total of functional cognition items across 10 domains 
(Language, Reading/Writing, Numeric Calculation, Limb Praxis, Visuospatial Func-
tion, Social Use of Language, Emotional Function, Attention, Memory, and Executive
Function) were administered to 128 individuals with stroke 49 acute (7–21 days post
onset) and 79 chronic (83–372 days post onset). Rasch and classical test analyses were
performed on 128 self-report ratings and 124 caregiver ratings. Neuropsychological
testing was performed with 62 randomly selected patients. RESULTS: Conﬁ rmatory 
factor analysis of each domain supported both unidimensionality and hypothesized
multidimensional structures for 5 of 10 domains with 1 domain only supporting a 
multidimensional structure. The all-item measure and separate domain measures 
showed excellent internal consistency (high person separation reliability and high 
Cronbach’s alphas). The all-item measure and domain measures (except Limb Praxis) 
produced expected item-difﬁ culty hierarchical orders. The all-item measure showed 
excellent person separation and except for Limb Praxis and Numeric Calculation 
(patient self-report), domain measures showed good person separation. While the All
Item measure showed no ﬂ oor or ceiling effects 5 of 10 domain measures showed 
ceiling effects. The domain measures showed fair-moderate correlations with analo-
gous neuropsychological test performance. CONCLUSIONS: With the exception of 
Limb Praxis, the ﬁ ndings support developing all-item and domain-speciﬁ c computer 
adaptive tests of functional cognition.
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OBJECTIVES: The primary aim of this study was to analyze quality of life (QOL) 
data from a Canadian population with type-2 diabetes in order to estimate the impact 
of a number of diabetes-related complications on utility measures of QOL. METHODS:
The EuroQol EQ-5D instrument was administered 1147 patients with type-2 diabetes.
After controlling for age, gender and duration of diabetes, utilities were estimated by
regressing the EQ-5D scores onto binary indicators for the presence of an event. The 
primary method of analysis was Ordinary Least Squares (OLS), and due to concerns 
over non-Normality, bootstrap standard errors (SE) were calculated. Both United
States and UK scoring algorithms were used to estimate respective utility decrements. 
RESULTS: 1,143 participants were included in the analysis. Using the UK algorithm 
and the OLS model, the utility decrements were as follows: myocardial infarction
(MI)  0.081 (SE  0.026), amputation  0.098 (SE  0.090), stroke  0.067 (SE 
 0.036), and kidney failure  0.158 (SE  0.073). The US algorithm produced the
following values: MI  0.059 (SE  0.017), amputation  0.063 (SE  0.059), stroke 
 0.046 (SE  0.023), and kidney failure  0.102 (SE  0.047). Estimates of these 
effects based on both the Tobit and censored least absolute deviations estimator
models were also reported and compared. CONCLUSIONS: This study used various 
regression models to estimate the decrements in EQ5D utility values associated with
several important complications commonly experienced in patients with diabetes. The
most signiﬁ cant impacts on QOL were associated with kidney failure and MI. The
decrements estimated using US scoring algorithm were smaller than using UK scoring 
algorithm. These utility values can be used to assess the outcome of interventions that 
reduce these diabetes-related complications and will have a great impact on future 
economic evaluations of diabetes management strategies in Canada.
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OBJECTIVES: To fully understand the multi-faceted impact of diabetes treatments, 
patients perceptions of health-related quality of life, treatment satisfaction and
treatment behavior must be assessed. Available diabetes patient reported outcome
(PRO) measures are speciﬁ c to type-1 or type-2 diabetes, treatment or delivery 
modality or are not inclusive of all potential impacts. The purpose of this study 
was to validate the Treatment Related Impact Measure (TRIM) for Diabetes and
Diabetes Device which were developed to assess the full range of impacts across 
diabetes type, all current delivery systems and diabetes treatments. METHODS:
The 60 item TRIM-Diabetes/-Device, developed in a prior study according to the
draft FDA guidelines, was validated in a web-based survey for measurement and
psychometric properties (factor structure, reliability, validity) for the total and each 
domain score. RESULTS: A total of 507 respondents completed the web-survey; 24
of 60 items were dropped due to redundancy, ceiling effects, poor factor loadings 
and/or poor conceptual ﬁ t, resulting in a 28 item TRIM-Diabetes and 8 item TRIM-
Device. A ﬁ ve-factor structure for the TRIM-diabetes with domains of treatment 
burden, daily life diabetes management, psychological health and compliance and 2 
domains of device function and device bother for the TRIM-Device were found. 
Internal consistency coefﬁ cients of the total score and each subscale ranged between
0.80 and 0.94 and test-retest reliability ranged from 0.71 to 0.89. All pre-speciﬁ ed 
hypotheses for convergent and known-groups validity were met. The estimated time
for completion of the combined measures is four minutes. CONCLUSIONS: The 
development of these measures has been conducted according to well deﬁ ned scientiﬁ c
principles, suggesting that the total score and each domain subscale, can be considered 
a brief, conceptually sound, rigorously developed PRO measure with strong evidence 
supporting the psychometric properties. Use of these measures in both clinical and 
research setting can facilitate targeted interventions with more positive treatment
outcomes.
